KELIM Score Predicts Outcome in Patients with Platinum-Resistant/Refractory Recurrent Ovarian Cancer
Fatih Kuş, Deniz Can Güven, Hasan Çağrı Yıldırım, Elvin Chalabıyev, Arif Akyıldız, Ömer Denizhan Tatar, Yigit Berk Sahin, Serez İleri, Ece Karaca, Neyran Kertmen, Zafer Arık
Abstract
Aim: To assess the prognostic role of the CA-125 elimination rate constant K (KELIM) score in platinum-resistant/refractory ovarian cancer patients receiving second-line treatment. Methods: A retrospective study was carried out including 117 patients with advanced-stage platinum-resistant/refractory ovarian cancer treated with liposomal doxorubicin ± bevacizumab. The KELIM score, calculated using CA-125 measurements within the first 100 days of chemotherapy, was used. Survival analyses were performed for overall survival (OS) and progression-free survival (PFS). Results: Higher KELIM scores were associated with a superior PFS and OS. Multivariate analysis confirmed the independent prognostic value of the KELIM score for OS. Validation cohorts showed consistent results. Conclusion: KELIM score may serve as a valuable prognostic marker for predicting OS and PFS in platinum-resistant/refractory ovarian cancer patients receiving second-line treatment. Prospective studies are needed for validation.